Cancer, Tumor
Conditions
Brief summary
Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.
Interventions
PROCEDURE3D-printed tumor mold for tissue sampling
3D-printed tumor mold for tissue sampling
Sponsors
Tampere University Hospital
Tampere University
Kuopio University Hospital
University of Eastern Finland
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
To be eligible for the study, the study candidate must: * be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (\<15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s)) * have a malignant or likely malignant tumor/tumors and undergo a surgical operation.
Exclusion criteria
To be eligible for the study, the study candidate cannot: * lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (\<15-year-old), the child is not eligible); * be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2. Histopathological evaluation | After the surgery upon review of the histopathological sample (within 3 months of the operation) | Rate of malignant/benign and higher/lower grade tumor tissue in the samples obtained using 3D-molds |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker evaluation from the samples obtained using 3D-mold | After the surgery throughout the study period and upon the completion of study recruitment within 3 months | Rate of presentation of biomarkers evaluated from the samples obtained using 3D-molds |
Countries
Finland
Contacts
CONTACTOtso Arponen, MD
Outcome results
None listed